一、可转债基本情况 股票代码：603707 股票简称：健友股份 公告编号：2025-040 债券代码：113579 债券简称：健友转债 南京健友生化制药股份有限公司关于不向下修正"健友转债"转股价格的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： ● 截至2025年5月23日，南京健友生化制药股份有限公司（以下简称"公司"）股票在任意连续三十个交 易日中已有十五个交易日的收盘价低于当期转股价格的90%，触发"健友转债"转股价格向下修正条款。 ● 经公司第五届董事会第十三次会议审议，公司董事会决定本次不向下修正转股价格，同时在未来6个 月内（即2025年5月24日至2025年11月23日），如再次触发"健友转债"转股价格向下修正条款的，亦不 提出向下修正方案。在此期间之后（从2025年11月24日起计算），若再次触发"健友转债"转股价格向下 修正条款，届时公司董事会将再次召开会议决定是否行使"健友转债"转股价格的向下修正权利。 7、公司于2023年7月7日起公司因实施2022年年度利润分配方案，"健友 ...

Group 1 - The company, Fujian Cosunter Pharmaceutical Co., Ltd., plans to issue A-shares to specific investors, with the proposal approved by the board and shareholders [2][3] - The issuance will target no more than 35 specific investors, including qualified institutional investors and individuals, with all subscriptions to be made in cash [3][4] - The pricing for the shares will be based on the average trading price over the 20 trading days prior to the pricing date, set at no less than 80% of that average [4] Group 2 - The total number of shares to be issued will not exceed 47,780,100, representing no more than 30% of the company's total share capital prior to the issuance [5] - The company aims to raise up to 976.87 million yuan, with funds allocated primarily for innovative drug research and development, traditional Chinese medicine industrialization, and working capital [5] - The company will initially use self-raised funds for projects until the raised funds are available, and if the actual net amount raised is less than planned, adjustments will be made based on project priorities [5] Group 3 - After the issuance, the shares subscribed by investors will be subject to a six-month lock-up period [6] - The issuance will not change the controlling shareholder or the actual controller of the company, nor will it affect the distribution of shares in a way that violates listing conditions [6] - The company has committed to measures to compensate for any dilution of immediate returns resulting from the issuance [6] Group 4 - The company has experienced continuous losses, with net profits of -132.18 million yuan, -354.23 million yuan, -199.54 million yuan, and -30.42 million yuan in recent periods, primarily due to increased R&D investments and price declines from centralized procurement policies [10][11] - The company is focusing on innovative drug development, which typically involves high costs and long timelines, and faces risks related to market acceptance and competition [9][10] - The company has established itself as a well-known player in the antiviral drug market, particularly in hepatitis B treatment, with a product portfolio that includes generics and innovative drugs [14]

Core Viewpoint - Fujian Guangshentang Pharmaceutical Co., Ltd. is preparing to issue A-shares to specific investors in 2025, with the aim of raising funds for various projects, including innovative drug research and traditional Chinese medicine industrialization. Group 1: Issuance Details - The company plans to issue no more than 47,780,100 A-shares, which will not exceed 30% of the total share capital before the issuance [12][14] - The total amount to be raised is not more than 976.87 million yuan, with funds allocated to innovative drug research, traditional Chinese medicine industrialization, and working capital [15] - The issuance will be conducted through a specific object issuance method, targeting up to 35 specific investors, including qualified institutional investors and natural persons [12][15] Group 2: Legal Compliance and Approval - The board of directors and the shareholders' meeting have approved the issuance plan, ensuring compliance with the Company Law and the company's articles of association [11][16] - The issuance is subject to approval from the Shenzhen Stock Exchange and registration by the China Securities Regulatory Commission [16][17] - The company has conducted thorough legal due diligence to ensure compliance with relevant laws and regulations [6][24] Group 3: Company Structure and Independence - Fujian Guangshentang Pharmaceutical is a legally established joint-stock company with independent operations, assets, and financial management [24][26] - The company has no business relationships with its controlling shareholders that would compromise its independence [25][26] - The controlling shareholder, Aohua Group, holds 17% of the shares, while the actual controllers have a combined voting power of 40.89% [27][28] Group 4: Financial and Operational Integrity - The company has maintained a clean legal record, with no significant violations or administrative penalties in the past three years [20][21] - The financial statements have been audited and comply with accounting standards, ensuring transparency and reliability [20][21] - The company has established a robust governance structure, with independent management and operational capabilities [25][26]

证券代码：688189 证券简称：南新制药 湖南南新制药股份有限公司 湖南南新制药股份有限公司 2024 年年度股东大会会议资料 《上 市公司股东会规则（2025 年修订）》以及《湖南南新制药股份有限公司章程》 《湖 南南新制药股份有限公司股东大会议事规则》等相关规定，特制定 2024 年年度 股东大会会议须知。 一、为保证本次大会的严肃性和正常秩序，切实维护与会股东（或股东代理 人）的合法权益，除出席会议的股东（或股东代理人）、公司董事、监事、高级 管理人员、见证律师及董事会邀请的人员外，公司有权依法拒绝其他无关人员进 入会场。 二、出席会议的股东及股东代理人须在会议召开前半小时到会议现场办理签 到手续，并按规定出示股东账户卡、身份证明文件或营业执照复印件（加盖公章）、 授权委托书等，上述登记材料均需提供复印件一份，个人登记材料复印件须个人 签字，法定代表人证明文件复印件须加盖公司公章，经验证后领取会议资料，方 可出席会议。 会议开始后，由会议主持人宣布现场出席会议的股东人数及其所持有表决权 的股份总数，在此之后进场的股东无权参与现场投票表决。 三、会议按照会议通知上所列顺序审议、表决议案。 二〇二五年六月 ...

证券代码：688189 证券简称：南新制药 公告编号：2025-024 湖南南新制药股份有限公司 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ? 股东大会召开日期：2025年6月13日 （三） 投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结 合的方式 召开地点：广东省广州市黄埔区开源大道 196 号广州南新制药有限公司 313 会议室 （五） 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 6 月 13 日 至2025 年 6 月 13 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东大会召开当日的交易时间段，即 9:15-9:25，9:30-11:30，13:00-15:00；通 过互联网投票平台的投票时间为股东大会召开当日的 9:15-15:00。 （六） 融资融券、转融通、约定购回业务账户和沪股通投资者的投票程序 涉及融资融券、转融通业务、约定购回业务相关账户以及沪股通投资者的投 票， ...

可控核聚变逆市爆发。 今日（5月23日），A股三大指数午后跳水。盘面上，可控核聚变板块强势，中洲特材（300963）、哈焊华通（301137）、雪人股份（002639）、王子新 材（002735）、融发核电（002366）等多股涨停；化学制药板块掀起涨停潮，新天地（301277）、多瑞医药（301075）、海辰药业（300584）、海森药业 （001367）、永安药业（002365）等股封板。 航运港口板块大幅下跌，南京港（002040）、连云港、*ST锦港（600190）跌停；游戏板块调整，冰川网络（300533）、星辉娱乐（300043）跌逾5%。 展望后市，东莞证券认为，当前货币政策宽松预期基本落地，后续需关注财政组合拳的发力衔接，重点涉及投资和消费两方面。短期内指数或维持高位震 荡，后续交易逻辑可能从风险偏好修复转向政策发力对经济数据的传导。金融、公用事业、汽车和TMT等板块值得重点关注。 4连板牛股今日跌停 今日，连续斩获4个涨停板的牛股棕榈股份（002431）突发跌停，收盘仍有26.7万手封单。公司昨日晚间发布股票交易异常波动公告，表明除已披露的信 息外，公司不存在应披露而未披露的重大事项，请广大 ...

龙虎榜机构热股 今天机构龙虎榜上榜31只个股，净买入16只，净卖出15只。当日机构买入最多的个股前三位是：一心堂（1.02亿）、新天地（7950万）、阳谷华泰（6672 万） | 上榜热股 | 实时涨跌幅 ◆ 买/卖家数 ◆ | | | --- | --- | --- | | 一心堂 | +10.01% | 3/2 | | 002727.SZ | | | | 新天地 | +20.02% | 2/2 | | 301277.SZ | | | | 阳谷华泰 | +19.97% | 2/1 | | 300121.SZ | | | 一心堂 龙虎榜显示，今日3家机构净买入1.02亿。 公司是国内连锁药店综合实力排名前三的企业 龙虎榜知名游资 一、核聚变 中洲特材 个股龙虎榜 核电公司的上游供应商，生产的阀门、焊材等产品已为中核、中广核、国核等核电设施配套；自由锻造阀杆、阀瓣、热阀瓣应用于威海荣成石岛湾CAP1400 示范核电站 王子新材 个股龙虎榜 公司子公司宁波新容电器科技有限公司参与了核聚变项目，电容器产品能应用到可控核聚变中的磁体电源项目 5月23日，行情数据显示，美核电股盘后集体大涨。Altman持股的Oklo涨 ...

今天，A股三大指数午后集体回调。全市场成交额11826亿元，较上日增加429亿元。医药板块逆势走 强，CRO、减肥药、化学制药等方向领涨。 14:00左右， 多只沪深300ETF量能显著放大 。截至收盘，华泰柏瑞沪深300ETF成交额近34亿元，易方 达沪深300ETF、嘉实沪深300ETF成交额显著放量。 截至收盘，沪指跌0.94%，深证成指跌0.85%，创业板指跌1.18%。板块方面，可控核聚变、贵金属、创 新药、维生素等板块涨幅居前，港口、游戏、算力、电力等板块跌幅居前。 赛力斯全天成交额超100亿元 赛力斯涨停，全天成交额超100亿元。 关注" 新华网财经 "视频号 更多财经资讯等你来看 渤海证券称，长期来看，美国居高不下的债务和赤字率、潜在的再通胀风险、全球复杂的地缘局势以及 多国央行购金等因素均对金价形成支撑。当前宏观情绪缓和背景下需关注短期波动，而长期基本面利好 因素仍存，黄金具备战略配置价值。 知名黄金分析师Jordan Roy-Byrne认为，黄金价格在年底有可能达到3700美元/盎司。金价将在未来12个 月内达到4400美元至4500美元/盎司。此外，白银价格也将突破100美元/盎司。 （ ...

华纳药厂688799 69.00分综合得分 较强 时间: 2025年5月23日星期五 趋势方向 主力成本分析 49.51 元 当日主力成本 46.66 元 5日主力成本 60日主力成本 周期内涨跌停 过去一年内该股 涨停 0次 跌停 44.24 元 20日主力成本 41.42 元 短期支撑位 48.61 中期压力位 0 次 技术面分析 47.99 短期压力位 43.21 2025年05月23日的资金流向数据方面 41.49 中期支撑位 | 主力资金净流入4478.66万元 | | --- | | 占总成交额15% | | 超大单净流入2486.40万元 | | 大单净流入1992.26万元 | | 散户资金净流出13.26万 | 关联行业/概念板块 化学制药 1.63%、婴童概念 -1.03%、病毒防治 0.13%、流感 0.77%等 股价突破短期压力位，短线有望走强； 股价突破中期压力位，中线有望走强 K线形态 ★多方炮★ 在底部出现有上涨可能，在中间出现有可能是上涨中继，顶部出现是复合见顶信号 资金流数据 （以上内容为自选股写手差分机完成，仅作为用户看盘参考，不能作为操作依据。） 风险提示：以上内容仅作为 ...

Market Overview - On May 23, A-shares experienced a collective pullback, with the Shanghai Composite Index down 0.94% closing at 3348.37 points, the Shenzhen Component down 0.85% at 10132.41 points, and the ChiNext Index down 1.18% at 2021.50 points [1] - The trading volume in the Shanghai and Shenzhen markets reached 115.56 billion, an increase of 52.9 billion compared to the previous day [1] - The market saw more stocks decline than rise, with over 1100 stocks increasing and more than 50 hitting the daily limit up [1] Sector Performance - Precious metals, chemical pharmaceuticals, and medical services sectors showed the highest gains, while shipping ports, gaming, trade, internet services, and diversified finance sectors faced the largest declines [1] - The market's cautious sentiment was reflected in the trading patterns, with significant fluctuations observed in micro-cap stocks and the North Exchange [3][5] Notable Stocks - Wangzi New Materials saw a significant price increase of nearly 60% since May 15, driven by developments in controllable nuclear fusion projects [7] - The stock experienced high volatility, with daily trading ranges exceeding 20% on May 21 and 16.01% on May 23, indicating strong market speculation and liquidity risks [7] - Heng Rui Pharmaceutical's H-shares debuted on the Hong Kong Stock Exchange, surging approximately 37% at one point, with a market capitalization exceeding 380 billion HKD [9][11] Investment Sentiment - Analysts remain cautiously optimistic about the market's future, suggesting a continuation of index fluctuations and sector rotations [9] - The pharmaceutical sector is expected to regain stability and growth, supported by ongoing innovations and favorable policies [12] - The biotechnology ETF saw an increase of over 1%, reflecting positive sentiment in the biopharmaceutical industry [12]